DJIA 18,232.02 -53.72 -0.29%
NASDAQ 5,089.36 -1.43 -0.03%
S&P 500 2,126.06 -4.76 -0.22%
market minute promo

5.01 0.01 (0.20%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

OREX $5.01 0.20%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $4.99
Previous Close $5.00
Daily Range $4.92 - $5.09
52-Week Range $3.11 - $9.37
Market Cap $627.4M
P/E Ratio -21.74
Dividend (Yield) $0.00 (0.0%)
Volume 1,716,994
Average Daily Volume 3,460,362
Current FY EPS -$0.67

Sector

Healthcare

Industry

Drug Makers

Orexigen Therapeutics, Inc. (OREX) Description

A biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system, disorders, with an initial focus on obesity. Website: http://www.orexigen.com/

News & Commentary Rss Feed

Orexigen Therapeutics, Inc. Goes From Biotech Beauty to Dreadful Drugmaker

A double dose of bad news for the obesity drugmaker.

Orexigen: Contrave Sales On The Cusp Of Anti-Obesity Leadership - Do Not Celebrate Yet

Arena: Belviq Sales Take Big Step Back - Advertising Needed

Orexigen: Contrave Sales Flattening - Europe Needed To Spur Numbers

Vivus: Qsymia Sales Win The Week, But Is It Enough?

Orexigen Therapeutics Retains Prescribers' And Analysts' Support

Which of These Growth Stocks Is Most Worthy of Your Money?

Amarin Corp. and Arena Pharmaceuticals were once high-flying biotech stocks. Since the commercial launch of their respective flagship products, though, their shares have fallen in a big way. In this article, I consider which stock has the better chance of recapturing its former glory going forward.

Seeking Alpha's Biotech Weekly: Orexigen's Wreck, Stagnant Gilead, And More

Orexigen Therapeutics: Problems Associated With Early Data Release

Orexigen Plummets After Release Of 50% Interim Results, But Is This The End?

See More OREX News...

OREX's Top Competitors

OREX $5.01 (0.20%)
Current stock: OREX
GILD $111.71 (0.44%)
Current stock: GILD
AMGN $163.59 (-0.15%)
Current stock: AMGN
BIIB $398.68 (-0.62%)
Current stock: BIIB